Jean Philippe Galanaud, Jean Pierre Laroch, and Marc Righini on Historical Treatments of DVT
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”The history and historical treatments of deep vein thrombosis: toward the era of new anticoagulants
By Jean Philippe Galanaud, Jean Pierre Laroch, and Marc Righini
• Context: Over centuries, the management of deep vein thrombosis (DVT) has evolved from empirical bloodletting to the precision of direct oral anticoagulants (DOACs).
• Overview: This historical review traces how DOACs revolutionized therapy—simplifying treatment, redefining duration and intensity, and reshaping clinical guidelines.
• Reflection: Despite progress, the “philosopher’s stone” of anticoagulation—perfect safety without loss of efficacy—remains elusive. Novel FXI/XIa inhibitors and AI-guided individualized therapy may herald the next transformation in DVT care.”
Read the full article in JTH.
Article: The history and historical treatments of deep vein thrombosis: toward the era of new anticoagulants
Authors: Jean Philippe Galanaud, Jean Pierre Laroch, Marc Righini
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 26, 2025, 15:21Patricia Simal Presented the Spanish National Health System's Stroke Strategy at WSC 2025
-
Oct 26, 2025, 14:32Paula Boldo on Sex-Stratified Genetic Risk of Stroke at WSC 2025
-
Oct 26, 2025, 14:08Sarah Matuja on Implementing Acute Stroke Services in Sub-Saharan Africa at WSC 2025
-
Oct 26, 2025, 13:43Hajer Ali Sinan on The Role of Fibrin-Related Biomarkers at IFRS Congress
-
Oct 25, 2025, 10:13Meet the 2025 WSO Award Winners for Their Extensive Contributions to Stroke Science
-
Oct 26, 2025, 15:04Nita Radhakrishnan and Colleagues on Inherited Haematological Conditions
-
Oct 26, 2025, 14:55Anirban Sen Gupta on Biosynthetic Blood Surrogates Current State-of-Art
-
Oct 26, 2025, 12:24Jean Philippe Galanaud, Jean Pierre Laroch, and Marc Righini on Historical Treatments of DVT
-
Oct 24, 2025, 12:08Julián Alejandro Rivillas Compares Tenecteplase to Low-dose Alteplase: TRACE-5 Interim Phase II Results
-
Oct 24, 2025, 12:03Melissa Glasner on Integration of Gene Therapy Into Hemophilia Care
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 25, 2025, 09:32Sylaja Pn Wins 2025 WSO Presidential Award
-
Oct 25, 2025, 08:21Courtney Lawrence: Listen. Empower. Deliver. Save Lives!
-
Oct 25, 2025, 08:14Hema Tallman on Incredible Opportunity to Participate in the PPTA 2025 Meetings
-
Oct 24, 2025, 11:28Louise Bannon and Thomas Reiser Thank World Thrombosis Day Supporters Around The World
-
Oct 24, 2025, 10:48Melanie Daniel Congratulates Mickael Rosa and Antoine Rauch on Winning Bernd R. Binder Prize